CAMBRIDGE, Mass. & BERGISCH GLADBACH, Germany -- -- Miltenyi Biotec announced today that the U.S. Food and Drug Administration has approved the company's CliniMACS CD34 Reagent System as a Humanitarian Use Device for the prevention of graft-versus-host disease in patients with acute myeloid leukemia in first complete remission undergoing allogeneic ... (more)
http://ift.tt/1mCugcS
http://ift.tt/1mCugcS
No comments:
Post a Comment